

Patient Information	Specimen Information	Client Information
SMITH, WILLIAM DOB: 10/11/1962 AGE: 58 Gender: M Fasting: U Phone: NG Patient ID: NG	Specimen: AL185375A Requisition: 4415165 Collected: 01/20/2021 / 10:00 CST Received: 01/20/2021 / 23:14 CST Reported: 01/21/2021 / 14:12 CST	Client #: 49100638 QATL0000 TUCK, PAMELA P AUM NURSING CARE CENTER 7461 EAST DRIVE #102 MONTGOMERY, AL 36117

Test Name	In Range	Out Of Range	Reference Range	Lab
COMPREHENSIVE METABOLIC PANEL				AT
GLUCOSE	95		65-99 mg/dL	
			Fasting reference interval	
UREA NITROGEN (BUN)	22		7-25 mg/dL	
CREATININE	1.19		0.70-1.33 mg/dL	
For patients >49 years of age, the reference limit for Creatinine is approximately 13% higher for people identified as African-American.				
eGFR NON-AFR. AMERICAN	67		> OR = 60 mL/min/1.73m2	
eGFR AFRICAN AMERICAN	78		> OR = 60 mL/min/1.73m2	
BUN/CREATININE RATIO	NOT APPLICABLE		6-22 (calc)	
SODIUM	137		135-146 mmol/L	
POTASSIUM	4.0		3.5-5.3 mmol/L	
CHLORIDE	101		98-110 mmol/L	
CARBON DIOXIDE	26		20-32 mmol/L	
CALCIUM	10.1		8.6-10.3 mg/dL	
PROTEIN, TOTAL	7.3		6.1-8.1 g/dL	
ALBUMIN	4.5		3.6-5.1 g/dL	
GLOBULIN	2.8		1.9-3.7 g/dL (calc)	
ALBUMIN/GLOBULIN RATIO	1.6		1.0-2.5 (calc)	
BILIRUBIN, TOTAL	0.6		0.2-1.2 mg/dL	
ALKALINE PHOSPHATASE	91		35-144 U/L	
AST	22		10-35 U/L	
ALT	27		9-46 U/L	
URIC ACID		8.4 H	4.0-8.0 mg/dL	AT
Therapeutic target for gout patients: <6.0 mg/dL				
TSH	2.36		0.40-4.50 mIU/L	AT
CBC (INCLUDES DIFF/PLT)				AT
WHITE BLOOD CELL COUNT	8.5		3.8-10.8 Thousand/uL	
RED BLOOD CELL COUNT	5.74		4.20-5.80 Million/uL	
HEMOGLOBIN	17.0		13.2-17.1 g/dL	
HEMATOCRIT	49.9		38.5-50.0 %	
MCV	86.9		80.0-100.0 fL	
MCH	29.6		27.0-33.0 pg	
MCHC	34.1		32.0-36.0 g/dL	
RDW	13.1		11.0-15.0 %	
PLATELET COUNT	256		140-400 Thousand/uL	
MPV	10.7		7.5-12.5 fL	
ABSOLUTE NEUTROPHILS	5763		1500-7800 cells/uL	
ABSOLUTE LYMPHOCYTES	1683		850-3900 cells/uL	
ABSOLUTE MONOCYTES	876		200-950 cells/uL	
ABSOLUTE EOSINOPHILS	102		15-500 cells/uL	
ABSOLUTE BASOPHILS	77		0-200 cells/uL	
NEUTROPHILS	67.8		%	
LYMPHOCYTES	19.8		%	
MONOCYTES	10.3		%	
EOSINOPHILS	1.2		%	
BASOPHILS	0.9		%	

Patient Information	Specimen Information	Client Information
SMITH, WILLIAM DOB: 10/11/1962 AGE: 58 Gender: M Fasting: U Patient ID: NG	Specimen: AL185375A Collected: 01/20/2021 / 10:00 CST Received: 01/20/2021 / 23:14 CST Reported: 01/21/2021 / 14:12 CST	Client #: 49100638 TUCK, PAMELA P

Test Name	In Range	Out Of Range	Reference Range	Lab
PSA, TOTAL	0.4		< OR = 4.0 ng/mL	AT

The total PSA value from this assay system is standardized against the WHO standard. The test result will be approximately 20% lower when compared to the equimolar-standardized total PSA (Beckman Coulter). Comparison of serial PSA results should be interpreted with this fact in mind.

This test was performed using the Siemens chemiluminescent method. Values obtained from different assay methods cannot be used interchangeably. PSA levels, regardless of value, should not be interpreted as absolute evidence of the presence or absence of disease.

Patient Information	Specimen Information	Client Information
SMITH, WILLIAM DOB: 10/11/1962 AGE: 58 Gender: M Fasting: U Patient ID: NG	Specimen: AL185375A Collected: 01/20/2021 / 10:00 CST Received: 01/20/2021 / 23:14 CST Reported: 01/21/2021 / 14:12 CST	Client #: 49100638 TUCK, PAMELA P

SARS CoV 2 (COVID-19) Tests

Test Name	Result	Reference Range	Lab
SARS CoV 2 SEROLOGY (COVID-19) AB (IGG), IA			AT
SARS CoV 2 AB IGG	NEGATIVE		
Reference range: Negative This test is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. Results are for the detection of SARS-CoV-2 antibodies. IgG antibodies to SARS-CoV-2 are generally detectable in blood several days after initial infection, although the duration of time antibodies are present post-infection is not well characterized. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity. Individuals may have detectable virus by molecular testing present for several weeks following seroconversion. Negative results do not preclude acute SARS-CoV-2 infection. This test should not be used to diagnose acute SARS-CoV-2 infection. If acute infection is suspected, direct testing by molecular methods for SARS-CoV-2 is necessary. False positive results for the test may occur due to cross-reactivity from pre-existing antibodies or other possible causes. Please review the "Fact Sheets" available for health care providers and patients using the following websites: QuestDiagnostics.com/home/Covid-19/HCP/antibody/fact-sheet2 QuestDiagnostics.com/home/Covid-19/Patients/antibody/fact-sheet2 This test has been authorized by the FDA under an Emergency Use Authorization (EUA) for use by authorized laboratories. The FDA authorized labeling is available on the Quest Diagnostics website: www.QuestDiagnostics.com/Covid19 For additional information please refer to http://education.questdiagnostics.com/faq/FAQ219 (This link is being provided for informational/educational purposes only.)			
Physician Comments:			

PERFORMING SITE:

AT QUEST DIAGNOSTICS-ATLANTA, 1777 MONTREAL CIRCLE, TUCKER, GA 30084-6802 Laboratory Director: ANDREW N YOUNG, MD, PHD, CLIA: 11D0255931

LIST OF RESULTS PRINTED IN THE OUT OF RANGE COLUMN:

URIC ACID	8.4 H	4.0-8.0 mg/dL	AT
Therapeutic target for gout patients: <6.0 mg/dL			